PE20030104A1 - Anticuerpos humanos para cd154 - Google Patents
Anticuerpos humanos para cd154Info
- Publication number
- PE20030104A1 PE20030104A1 PE2001000244A PE2001000244A PE20030104A1 PE 20030104 A1 PE20030104 A1 PE 20030104A1 PE 2001000244 A PE2001000244 A PE 2001000244A PE 2001000244 A PE2001000244 A PE 2001000244A PE 20030104 A1 PE20030104 A1 PE 20030104A1
- Authority
- PE
- Peru
- Prior art keywords
- phe
- variable domain
- sequence
- chain
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE ENLACE DE CD154 QUE COMPRENDE UN SITIO DE ENLACE DE ANTIGENO CON POR LO MENOS UN DOMINIO VARIABLE DE CADENA PESADA DE INMUNOGLOBULINA (VH) QUE COMPRENDE SECUENCIAS DE LAS REGIONES HIPERVARIABLES CDR1, CDR2 Y CDR3 TENIENDO LA CDR1 SECUENCIA DE AMINOACIDOS Asn-Phe-Ala-Phe-Asn, TENIENDO LA CDR2 LA SECUENCIA DE AMINOACIDO Arg-Ile-Leu-Pro-Ser-Leu-Asp-Ile-Ala-Ser Y LA CDR3 UNA SECUENCIA DE Glu-Val-Asp-Gly-Gly-Phe Y SUS EQUIVALENTES DIRECTOS. SE REFIERE TAMBIEN A UNA MOLECULA DE ENLACE CD154 QUE COMPRENDE CUANDO MENOS UN SITIO DE ENLACE: a) UNA CADENA PESADA QUE COMPRENDE UN DOMINO VARIABLE IDENTICA A LA SEQ No:2 EMPEZANDO CON EL AMINOACIDO EN POSICION 1 Y TERMINANDO EN LA POSICION 118 Y LA PARTE CONSTANTE DE UNA CADENA PESADA HUMANA; b) UNA CADENA LIGERA QUE COMPRENDE UN DOMINIO VARIABLE QUE TIENE LA SEQ No: 4 EMPEZANDO EN POSICION 1 Y TERMINANDO EN POSICION 107 Y LA PARTE CONSTANTE DE LA CADENA LIGERA HUMANA. LA MOLECULA ES UTIL PARA LA INHIBICION DE UNA RESPUESTA INMUNE MEDIADA POR LAS INTERACCIONES DE LAS CELULAS POSITIVAS PARA CD154 CON CELULAS POSITIVAS PARA CD40 UTIL PARA PROCESOS INFLAMATORIOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0006398.2A GB0006398D0 (en) | 2000-03-16 | 2000-03-16 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030104A1 true PE20030104A1 (es) | 2003-03-10 |
Family
ID=9887779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000244A PE20030104A1 (es) | 2000-03-16 | 2001-03-14 | Anticuerpos humanos para cd154 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7169389B2 (es) |
EP (1) | EP1263959A1 (es) |
JP (1) | JP2003526371A (es) |
AR (1) | AR027976A1 (es) |
AU (2) | AU4835001A (es) |
CA (1) | CA2400106A1 (es) |
CO (1) | CO5280086A1 (es) |
GB (1) | GB0006398D0 (es) |
PE (1) | PE20030104A1 (es) |
WO (1) | WO2001068860A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072882A1 (fr) * | 1999-06-01 | 2000-12-07 | Eisai Co., Ltd. | Agents prophylactiques du purpura thrombocytopenique idiopathique |
JP3845735B2 (ja) * | 2002-04-03 | 2006-11-15 | 学校法人慶應義塾 | Cd40lアンタゴニストを有効成分とする天疱瘡治療剤 |
US7883538B2 (en) * | 2002-06-13 | 2011-02-08 | Guided Delivery Systems Inc. | Methods and devices for termination |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
ES2216707B1 (es) * | 2003-04-08 | 2005-12-16 | Josep Maria Aran Perramon | Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes. |
WO2005003175A2 (en) * | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
GB0314461D0 (en) * | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
RS53476B (en) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
EP2594591B1 (en) | 2005-08-11 | 2018-06-06 | Arpi Matossian-Rogers | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
AU2012241141B2 (en) * | 2005-08-11 | 2015-08-20 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
EP1968386A4 (en) * | 2005-12-15 | 2009-07-22 | Univ New York State Res Found | METHOD FOR TREATING UNDERFUNCTION OF THE IMMUNE SYSTEM BY REGULATING THE CD40 LIGAND EXPRESSION |
US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008103378A2 (en) * | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
US20100311767A1 (en) * | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
US20090258343A1 (en) * | 2007-10-19 | 2009-10-15 | Reiter Paul C | Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 Ligand/CD154, A CD4+ T cell equivalent and the simultaneous detection of HIV infection via HIV antibody detection |
WO2009054921A1 (en) * | 2007-10-19 | 2009-04-30 | Reiter Paul C | Semi-quantitative immunochromatographic device and method for the determination of hiv/aids immune-status via measurement of soluble cd40 ligand/cd 154, a cd4+ t cell equivalent |
GB0721752D0 (en) * | 2007-11-06 | 2007-12-19 | Univ Southampton | Configurable electronic device and method |
ES2650267T3 (es) | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
KR101758942B1 (ko) | 2009-09-24 | 2017-07-17 | 유씨비 파마, 에스.에이. | 박테리아 숙주 균주 |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
CN103649124B (zh) | 2011-07-13 | 2016-04-13 | Ucb医药有限公司 | 表达重组dsbc的细菌宿主菌株 |
LT2766395T (lt) | 2011-10-13 | 2020-03-25 | Bristol-Myers Squibb Company | Antikūno polipeptidai, kaip cd40l antagonistai |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
KR101752280B1 (ko) | 2015-03-31 | 2017-06-30 | 서울대학교산학협력단 | 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주 |
KR20160132694A (ko) * | 2015-05-11 | 2016-11-21 | 주식회사 프로젠 | Cd154에 특이적으로 결합하는 항체 |
MX2018000548A (es) * | 2015-07-14 | 2018-09-26 | Immunext Inc | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. |
EA201890434A1 (ru) | 2015-08-05 | 2018-10-31 | Янссен Байотек, Инк. | Антитела к cd154 и способы их применения |
RU2018122255A (ru) | 2015-11-27 | 2019-12-19 | Аблинкс Нв | Полипептиды, ингибирующие cd40l |
EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
AU2018271915A1 (en) | 2017-05-24 | 2019-11-28 | Als Therapy Development Institute | Therapeutic anti-CD40 ligand antibodies |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
EP3883634A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
-
2000
- 2000-03-16 GB GBGB0006398.2A patent/GB0006398D0/en not_active Ceased
-
2001
- 2001-03-14 PE PE2001000244A patent/PE20030104A1/es not_active Application Discontinuation
- 2001-03-14 EP EP01921337A patent/EP1263959A1/en not_active Withdrawn
- 2001-03-14 US US10/221,529 patent/US7169389B2/en not_active Expired - Fee Related
- 2001-03-14 CO CO01020763A patent/CO5280086A1/es not_active Application Discontinuation
- 2001-03-14 WO PCT/EP2001/002875 patent/WO2001068860A1/en not_active Application Discontinuation
- 2001-03-14 AR ARP010101184A patent/AR027976A1/es unknown
- 2001-03-14 AU AU4835001A patent/AU4835001A/xx active Pending
- 2001-03-14 JP JP2001567344A patent/JP2003526371A/ja active Pending
- 2001-03-14 CA CA002400106A patent/CA2400106A1/en not_active Abandoned
- 2001-03-14 AU AU2001248350A patent/AU2001248350B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2001068860A1 (en) | 2001-09-20 |
JP2003526371A (ja) | 2003-09-09 |
AR027976A1 (es) | 2003-04-23 |
AU4835001A (en) | 2001-09-24 |
US20040038293A1 (en) | 2004-02-26 |
CO5280086A1 (es) | 2003-05-30 |
US7169389B2 (en) | 2007-01-30 |
EP1263959A1 (en) | 2002-12-11 |
CA2400106A1 (en) | 2001-09-20 |
AU2001248350B2 (en) | 2004-10-14 |
GB0006398D0 (en) | 2000-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030104A1 (es) | Anticuerpos humanos para cd154 | |
AR035581A1 (es) | Anticuerpos para il-1beta humana | |
HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
HRP20020693B1 (en) | HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE | |
RS51908B (en) | CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
PE20011219A1 (es) | ANTICUERPOS PARA IL-1ß HUMANA | |
RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
RS52860B (en) | ANTI-ILT7 ANTITELO | |
PE20050925A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
RS52332B (en) | HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS | |
IL299221A (en) | CD3 binding antibodies | |
RS53819B1 (en) | ANTI-ACTIVIN ANTIBODIES AND THEIR APPLICATIONS | |
RS54088B1 (en) | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | |
PE20020125A1 (es) | Moleculas de enlace a mcp-1 | |
PE20020871A1 (es) | Moleculas de enlace terapeuticas | |
NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
RS54271B1 (en) | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) | |
RS54424B1 (en) | HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES | |
RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |